Omega Healthcare Investors (OHI) Financials

Omega Healthcare Investors (NYSE: OHI) has shown a multi-year pattern of improving cash generation from operations alongside a rebound in revenue in 2025 after weaker 2023–2024 results. The company continues to carry a sizable debt load, and recent quarters have featured meaningful cash outflows from financing activities. Below is a concise, bullet-point view of the key four-year trends based on the provided quarterly statements.

• Core operating cash flow has firmed over the last four years, with net cash from continuing operating activities totaling about $230.62 million in Q4 2025, up from roughly $153.68 million in Q4 2022 and about $164.98 million in Q4 2023. This indicates stronger ongoing cash generation from the business even as other items fluctuate.
• Total revenue rebounded in 2025, reaching about $229.13 million in Q4 2025, up from $178.86 million in Q4 2023 and $219.04 million in Q4 2024. This reflects a meaningful improvement in period-to-period top-line performance compared with the 2023 trough.
• Net income attributable to common shareholders rose to roughly $164.84 million in Q4 2025 from about $113.86 million in Q4 2023, complemented by higher diluted earnings per share (EPS) of $0.56 in Q4 2025 vs $0.46 in Q4 2023. This suggests improved profitability and earnings power alongside the revenue recovery.
• Dividends per share remained steady at $0.67 across the period, indicating ongoing cash-return to shareholders despite fluctuations in quarterly earnings and financing activity.
• Net interest income remains negative across quarters (eg, Q4 2025 net interest income / expense of about -$7.56 million; Q3 2025 about -$13.30 million), reflecting ongoing funding costs and the structure of lease/financing in a REIT context. The magnitude of the swing is relatively contained, but it remains a headwind to net income.
• Total assets have trended higher, rising to about $10.60 billion by 2025 Q3 from roughly the mid-to-high $9 billion range in 2022–2024, signaling asset growth alongside the company’s acquisitions and financings.
• Long-term debt levels have remained sizable, hovering around $5.0 billion (e.g., around $4.99–$5.00 billion in 2025), indicating continued leverage typical of a healthcare REIT.
• Total equity and related components have stayed in the $3.7–5.3 billion range across the period, with total equity plus noncontrolling interests generally supporting the balance sheet alongside ongoing financing activity.
• Net change in cash and equivalents in Q4 2025 was a sizable negative ($-720.4 million), driven largely by financing outflows (notably debt repayments and dividend payments) despite positive operating cash flow. This highlights a heavy near-term cash outflow from financing activities.
• Net cash from financing activities in Q4 2025 was substantially negative (about $-940.46 million), underscoring continued reliance on financing activities to support debt service and distributions and the associated cash outflows in that quarter.